IL6 and COVID-19: The study authors found that angiotensin receptor blocker use was associated with a significantly improved COVID-19 outcome, in part due to lower circulating levels of mortality-predicting markers, including leukocytes, neutrophils, C-reactive protein, procalcitonin, and IL-6.